{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T01:13:30Z","timestamp":1785806010503,"version":"3.56.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Multiple myeloma (MM) is a prevalent hematologic malignancy characterized by abnormal proliferation of cloned plasma cells. Given the aggressive nature and drug resistance of MM cells, identification of novel genes could provide valuable insights for treatment. In this study we performed machine learning in the RNA microarray data of purified myeloma plasma cell samples from five independent MM cohorts with 957 MM patients, and identified O-GlcNAcylation transferase (<jats:italic>OGT<\/jats:italic>) and cell division cycle <jats:italic>27<\/jats:italic> (<jats:italic>CDC27<\/jats:italic>) as the key prognostic genes for MM. We demonstrated a close link between OGT and CDC27 in MM cells by knockdown of OGT with siOGT, pharmacological inhibition of O-GlcNAcylation with OSMI-1 and pharmacological accumulation of O-GlcNAcylation with Thiamet G. Using mass spectrometry and immunoprecipitation, we identified the O-GlcNAcylated CDC27 protein as a key target protein that may be directly downregulated by OSMI-1 in MM.1S cells. We further revealed that O-GlcNAcylation maintained CDC27 protein stability by blocking the autophagy-lysosome pathway (ALP). Moreover, we demonstrated the enhanced antitumor efficacy of combined OSMI-1 and bortezomib (BTZ) treatment in MM cells both in vivo and in vitro. Thus, this study identifies a novel function of O-GlcNAcylation-related ALP in regulating CDC27 protein stability and a potential therapeutic strategy for treating MM.<\/jats:p>","DOI":"10.1038\/s41401-025-01500-2","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T15:07:00Z","timestamp":1740150420000},"page":"2041-2055","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Inhibition of CDC27 O-GlcNAcylation coordinates the antitumor efficacy in multiple myeloma through the autophagy-lysosome pathway"],"prefix":"10.1038","volume":"46","author":[{"given":"Hai-qi","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren-cai","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie-na","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-han","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-peng","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-fang","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-mei","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-fang","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-wei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-yan","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kong-yang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"key":"1500_CR1","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","volume":"111","author":"RA Kyle","year":"2008","unstructured":"Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008;111:2962\u201372.","journal-title":"Blood"},{"key":"1500_CR2","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.3390\/biom12111647","volume":"12","author":"K Ding","year":"2022","unstructured":"Ding K, Jiang W, Jia H, Lei M. Synergistically anti-multiple myeloma effects: flavonoid, non-flavonoid polyphenols, and bortezomib. Biomolecules. 2022;12:1647.","journal-title":"Biomolecules"},{"key":"1500_CR3","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.3390\/ijms23031649","volume":"23","author":"S Das","year":"2022","unstructured":"Das S, Juliana N, Yazit NAA, Azmani S, Abu IF. Multiple myeloma: challenges encountered and future options for better treatment. Int J Mol Sci. 2022;23:1649.","journal-title":"Int J Mol Sci"},{"key":"1500_CR4","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/s41591-021-01232-w","volume":"27","author":"YC Cohen","year":"2021","unstructured":"Cohen YC, Zada M, Wang SY, Bornstein C, David E, Moshe A, et al. Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing. Nat Med. 2021;27:491\u2013503.","journal-title":"Nat Med"},{"key":"1500_CR5","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1136\/annrheumdis-2018-213615","volume":"77","author":"KY Ma","year":"2018","unstructured":"Ma KY, Li JY, Wang XH, Lin X, Du WH, Yang X, et al. TLR4+CXCR4+ plasma cells drive nephritis development in systemic lupus erythematosus. Ann Rheum Dis. 2018;77:1498\u2013506.","journal-title":"Ann Rheum Dis"},{"key":"1500_CR6","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1038\/s12276-022-00884-z","volume":"54","author":"SH Jung","year":"2022","unstructured":"Jung SH, Park SS, Lim JY, Sohn SY, Kim NY, Kim D, et al. Single-cell analysis of multiple myelomas refines the molecular features of bortezomib treatment responsiveness. Exp Mol Med. 2022;54:1967\u201378.","journal-title":"Exp Mol Med"},{"key":"1500_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40170-017-0169-9","volume":"5","author":"EA Zaal","year":"2017","unstructured":"Zaal EA, Wu W, Jansen G, Zweegman S, Cloos J, Berkers CR. Bortezomib resistance in multiple myeloma is associated with increased serine synthesis. Cancer Metab. 2017;5:7.","journal-title":"Cancer Metab"},{"key":"1500_CR8","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1158\/0008-5472.CAN-14-3400","volume":"75","author":"P Maiso","year":"2015","unstructured":"Maiso P, Huynh D, Moschetta M, Sacco A, Aljawai Y, Mishima Y, et al. Metabolic signature identifies novel targets for drug resistance in multiple myeloma. Cancer Res. 2015;75:2071\u201382.","journal-title":"Cancer Res"},{"key":"1500_CR9","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3390\/bioengineering10020173","volume":"10","author":"F Alharbi","year":"2023","unstructured":"Alharbi F, Vakanski A. Machine learning methods for cancer classification using gene expression data: a review. Bioengineering. 2023;10:173.","journal-title":"Bioengineering"},{"key":"1500_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.897862","volume":"13","author":"M Roman-Trufero","year":"2022","unstructured":"Roman-Trufero M, Auner HW, Edwards CM. Multiple myeloma metabolism - a treasure trove of therapeutic targets? Front Immunol. 2022;13:897862.","journal-title":"Front Immunol"},{"key":"1500_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2022.109886","volume":"357","author":"N Zhang","year":"2022","unstructured":"Zhang N, Jiang H, Zhang K, Zhu J, Wang Z, Long Z, et al. OGT as potential novel target: structure, function and inhibitors. Chem Biol Interact. 2022;357:109886.","journal-title":"Chem Biol Interact"},{"key":"1500_CR12","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.tcb.2023.03.008","volume":"33","author":"J Liu","year":"2023","unstructured":"Liu J, Cao X. Glucose metabolism of TAMs in tumor chemoresistance and metastasis. Trends Cell Biol. 2023;33:967\u201378.","journal-title":"Trends Cell Biol"},{"key":"1500_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13601-8","volume":"11","author":"H Nie","year":"2020","unstructured":"Nie H, Ju H, Fan J, Shi X, Cheng Y, Cang X, et al. O-GlcNAcylation of PGK1 coordinates glycolysis and TCA cycle to promote tumor growth. Nat Commun. 2020;11:36.","journal-title":"Nat Commun"},{"key":"1500_CR14","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.jhep.2018.02.003","volume":"68","author":"FF Duan","year":"2018","unstructured":"Duan FF, Wu H, Jia D, Wu W, Ren S, Wang L, et al. O-GlcNAcylation of RACK1 promotes hepatocellular carcinogenesis. J Hepatol. 2018;68:1191\u2013202.","journal-title":"J Hepatol"},{"key":"1500_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01677-z","volume":"8","author":"JL Wu","year":"2017","unstructured":"Wu JL, Chiang MF, Hsu PH, Tsai D, Hung K, Wang Y, et al. O-GlcNAcylation is required for B cell homeostasis and antibody responses. Nat Commun. 2017;8:1854.","journal-title":"Nat Commun"},{"key":"1500_CR16","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.3390\/cancers15051526","volume":"15","author":"A Aziz","year":"2023","unstructured":"Aziz A, Wang H, Wang Y, Li Z, Yang C, Ma Z, et al. Periplocin overcomes bortezomib resistance by suppressing the growth and down-regulation of cell adhesion molecules in multiple myeloma. Cancers. 2023;15:1526.","journal-title":"Cancers"},{"key":"1500_CR17","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70:440\u20136.","journal-title":"Cancer Res"},{"key":"1500_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2023.107980","volume":"244","author":"NCD Silva","year":"2024","unstructured":"Silva NCD, Albertini MK, Backes AR, Pena GDG. Machine learning for hospital readmission prediction in pediatric population. Comput Methods Programs Biomed. 2024;244:107980.","journal-title":"Comput Methods Programs Biomed"},{"key":"1500_CR19","doi-asserted-by":"publisher","first-page":"10451","DOI":"10.1039\/D0CS01275K","volume":"50","author":"A Saha","year":"2021","unstructured":"Saha A, Bello D, Fern\u00e1ndez-Tejada A. Advances in chemical probing of protein O-GlcNAc glycosylation: structural role and molecular mechanisms. Chem Soc Rev. 2021;50:10451\u201385.","journal-title":"Chem Soc Rev"},{"key":"1500_CR20","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1021\/acschembio.5b00004","volume":"10","author":"RF Ortiz-Meoz","year":"2015","unstructured":"Ortiz-Meoz RF, Jiang J, Lazarus MB, Orman M, Janetzko J, Fan C, et al. A small molecule that inhibits OGT activity in cells. ACS Chem Biol. 2015;10:1392\u20137.","journal-title":"ACS Chem Biol"},{"key":"1500_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114444","volume":"238","author":"X Li","year":"2022","unstructured":"Li X, Han J, Bujaranipalli S, He J, Kim EY, Kim H, et al. Structure-based discovery and development of novel O-GlcNAcase inhibitors for the treatment of Alzheimer\u2019s disease. Eur J Med Chem. 2022;238:114444.","journal-title":"Eur J Med Chem"},{"key":"1500_CR22","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1016\/j.biocel.2013.04.023","volume":"45","author":"M Sandri","year":"2013","unstructured":"Sandri M. Protein breakdown in muscle wasting: role of autophagy-lysosome and ubiquitin-proteasome. Int J Biochem Cell Biol. 2013;45:2121\u20139.","journal-title":"Int J Biochem Cell Biol"},{"key":"1500_CR23","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1080\/15384101.2019.1632138","volume":"18","author":"X Yuan","year":"2019","unstructured":"Yuan X, Ma R, Yang S, Jiang L, Wang Z, Zhu Z, et al. miR-520g and miR-520h overcome bortezomib resistance in multiple myeloma via suppressing APE1. Cell Cycle. 2019;18:1660\u20139.","journal-title":"Cell Cycle"},{"key":"1500_CR24","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.3390\/cancers14102518","volume":"14","author":"L Wu","year":"2022","unstructured":"Wu L, Huang Y, Sienkiewicz J, Sun J, Guiang L, Li F, et al. Bispecific BCMA-CD3 antibodies block multiple myeloma tumor growth. Cancers. 2022;14:2518.","journal-title":"Cancers"},{"key":"1500_CR25","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ctrv.2018.09.001","volume":"70","author":"P Robak","year":"2018","unstructured":"Robak P, Drozdz I, Szemraj J, Robak T. Drug resistance in multiple myeloma. Cancer Treat Rev. 2018;70:199\u2013208.","journal-title":"Cancer Treat Rev"},{"key":"1500_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00538-5","volume":"8","author":"S Wang","year":"2024","unstructured":"Wang S, Wang R, Hu D, Zhang C, Cao P, Huang J. Machine learning reveals diverse cell death patterns in lung adenocarcinoma prognosis and therapy. NPJ Precis Oncol. 2024;8:49.","journal-title":"NPJ Precis Oncol"},{"key":"1500_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04499-4","volume":"21","author":"Y Zheng","year":"2023","unstructured":"Zheng Y, Wang J, Ling Z, Zhang J, Zeng Y, Wang K, et al. A diagnostic model for sepsis-induced acute lung injury using a consensus machine learning approach and its therapeutic implications. J Transl Med. 2023;21:620.","journal-title":"J Transl Med"},{"key":"1500_CR28","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1056\/NEJMoa1504542","volume":"373","author":"AL Garfall","year":"2015","unstructured":"Garfall AL, Maus MV, Hwang WT, Lacey SF, Mahnke YD, Melenhorst JJ, et al. Chimeric antigen receptor T cells against CD19 for multiple myeloma. N Engl J Med. 2015;373:1040\u20137.","journal-title":"N Engl J Med"},{"key":"1500_CR29","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1158\/0008-5472.CAN-20-2946","volume":"81","author":"PSY Chong","year":"2021","unstructured":"Chong PSY, Chooi JY, Lim JSL, Toh SHM, Tan TZ, Chng WJ. SMARCA2 is a novel interactor of NSD2 and regulates prometastatic PTP4A3 through chromatin remodeling in t(4;14) multiple myeloma. Cancer Res. 2021;81:2332\u201344.","journal-title":"Cancer Res"},{"key":"1500_CR30","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/nrm.2017.22","volume":"18","author":"X Yang","year":"2017","unstructured":"Yang X, Qian K. Protein O-GlcNAcylation: emerging mechanisms and functions. Nat Rev Mol Cell Biol. 2017;18:452\u201365.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1500_CR31","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s10020-022-00544-y","volume":"28","author":"Q Lu","year":"2022","unstructured":"Lu Q, Zhang X, Liang T, Bai X. O-GlcNAcylation: an important post-translational modification and a potential therapeutic target for cancer therapy. Mol Med. 2022;28:115.","journal-title":"Mol Med"},{"key":"1500_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0522-0","volume":"9","author":"Y Liu","year":"2018","unstructured":"Liu Y, Cao Y, Pan X, Shi M, Wu Q, Huang T, et al. O-GlcNAc elevation through activation of the hexosamine biosynthetic pathway enhances cancer cell chemoresistance. Cell Death Dis. 2018;9:485.","journal-title":"Cell Death Dis"},{"key":"1500_CR33","doi-asserted-by":"publisher","first-page":"5200","DOI":"10.7150\/thno.27806","volume":"8","author":"F Zhou","year":"2018","unstructured":"Zhou F, Yang X, Zhao H, Liu Y, Feng Y, An R, et al. Down-regulation of OGT promotes cisplatin resistance by inducing autophagy in ovarian cancer. Theranostics. 2018;8:5200\u201312.","journal-title":"Theranostics"},{"key":"1500_CR34","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1042\/BST20150189","volume":"44","author":"R Trapannone","year":"2016","unstructured":"Trapannone R, Rafie K, van Aalten DM. O-GlcNAc transferase inhibitors: current tools and future challenges. Biochem Soc Trans. 2016;44:88\u201393.","journal-title":"Biochem Soc Trans"},{"key":"1500_CR35","doi-asserted-by":"publisher","DOI":"10.1111\/jpi.12765","volume":"71","author":"J Wu","year":"2021","unstructured":"Wu J, Tan Z, Li H, Lin M, Jiang Y, Liang L, et al. Melatonin reduces proliferation and promotes apoptosis of bladder cancer cells by suppressing O-GlcNAcylation of cyclin-dependent-like kinase 5. J Pineal Res. 2021;71:e12765.","journal-title":"J Pineal Res"},{"key":"1500_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-023-02954-2","volume":"23","author":"DE Lee","year":"2023","unstructured":"Lee DE, Lee GY, Lee HM, Choi SY, Lee SJ, Kwon OS. Synergistic apoptosis by combination of metformin and an O-GlcNAcylation inhibitor in colon cancer cells. Cancer Cell Int. 2023;23:108.","journal-title":"Cancer Cell Int"},{"key":"1500_CR37","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/nature09638","volume":"469","author":"MB Lazarus","year":"2011","unstructured":"Lazarus MB, Nam Y, Jiang J, Sliz P, Walker S. Structure of human O-GlcNAc transferase and its complex with a peptide substrate. Nature. 2011;469:564\u20137.","journal-title":"Nature"},{"key":"1500_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-35795-8","volume":"14","author":"JM Lee","year":"2023","unstructured":"Lee JM, Hammar\u00e9n HM, Savitski MM, Baek SH. Control of protein stability by post-translational modifications. Nat Commun. 2023;14:201.","journal-title":"Nat Commun"},{"key":"1500_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.402","volume":"7","author":"L Qiu","year":"2016","unstructured":"Qiu L, Wu J, Pan C, Tan X, Lin J, Liu R, et al. Downregulation of CDC27 inhibits the proliferation of colorectal cancer cells via the accumulation of p21Cip1\/Waf1. Cell Death Dis. 2016;7:e2074.","journal-title":"Cell Death Dis"},{"key":"1500_CR40","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s11033-024-09744-7","volume":"51","author":"Y Pouriafar","year":"2024","unstructured":"Pouriafar Y, Rostami S, Alizadghandforoush N, Barati M, Amini A, Safa M. CDC27 gene expression patterns as a potential biomarker in acute leukemia. Mol Biol Rep. 2024;51:865.","journal-title":"Mol Biol Rep"},{"key":"1500_CR41","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41420-023-01781-8","volume":"10","author":"Z Cui","year":"2024","unstructured":"Cui Z, Cong M, Yin S, Li Y, Ye Y, Liu X, et al. Role of protein degradation systems in colorectal cancer. Cell Death Discov. 2024;10:141.","journal-title":"Cell Death Discov"},{"key":"1500_CR42","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1182\/bloodadvances.2022007875","volume":"7","author":"GJJE Heynen","year":"2023","unstructured":"Heynen GJJE, Baumgartner F, Heider M, Patra U, Holz M, Braune J, et al. SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma. Blood Adv. 2023;7:469\u201381.","journal-title":"Blood Adv"},{"key":"1500_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-83829-2","volume":"11","author":"Y Aisen","year":"2021","unstructured":"Aisen Y, Gatt ME, Hertz R, Smeir E, Bar-Tana J. Suppression of multiple myeloma by mitochondrial targeting. Sci Rep. 2021;11:5862.","journal-title":"Sci Rep"},{"key":"1500_CR44","doi-asserted-by":"publisher","first-page":"9709","DOI":"10.1002\/cam4.5679","volume":"12","author":"K Abe","year":"2023","unstructured":"Abe K, Ikeda S, Nara M, Kitadate A, Tagawa H, Takahashi N. Hypoxia-induced oxidative stress promotes therapy resistance via upregulation of heme oxygenase-1 in multiple myeloma. Cancer Med. 2023;12:9709\u201322.","journal-title":"Cancer Med"},{"key":"1500_CR45","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/s41586-023-06089-2","volume":"618","author":"A Gonz\u00e1lez","year":"2023","unstructured":"Gonz\u00e1lez A, Covarrubias-Pinto A, Bhaskara RM, Glogger M, Kuncha SK, Xavier A, et al. Ubiquitination regulates ER-phagy and remodelling of endoplasmic reticulum. Nature. 2023;618:394\u2013401.","journal-title":"Nature"},{"key":"1500_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.468","volume":"5","author":"C Kao","year":"2014","unstructured":"Kao C, Chao A, Tsai CL, Chuang WC, Huang WP, Chen GC, et al. Bortezomib enhances cancer cell death by blocking the autophagic flux through stimulating ERK phosphorylation. Cell Death Dis. 2014;5:e1510.","journal-title":"Cell Death Dis"},{"key":"1500_CR47","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s12185-016-2016-0","volume":"104","author":"M Ri","year":"2016","unstructured":"Ri M. Endoplasmic-reticulum stress pathway-associated mechanisms of action of proteasome inhibitors in multiple myeloma. Int J Hematol. 2016;104:273\u201380.","journal-title":"Int J Hematol"},{"key":"1500_CR48","first-page":"1501","volume":"109","author":"S Marino","year":"2024","unstructured":"Marino S, Petrusca DN, Bishop RT, Anderson JL, Sabol HM, Ashby C, et al. Pharmacologic targeting of the p62 ZZ domain enhances both anti-tumor and bone-anabolic effects of bortezomib in multiple myeloma. Haematologica. 2024;109:1501\u201313.","journal-title":"Haematologica"},{"key":"1500_CR49","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29:2259\u201367.","journal-title":"Nat Med"},{"key":"1500_CR50","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1038\/s43018-024-00763-8","volume":"5","author":"M Rade","year":"2024","unstructured":"Rade M, Grieb N, Weiss R, Sia J, Fischer L, Born P, et al. Single-cell multiomic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma. Nat Cancer. 2024;5:1318\u201333.","journal-title":"Nat Cancer"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01500-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01500-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01500-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T08:02:24Z","timestamp":1751011344000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01500-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,21]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1500"],"URL":"https:\/\/doi.org\/10.1038\/s41401-025-01500-2","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,21]]},"assertion":[{"value":"21 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}